NZ329431A - Purine derivatives and medicaments thereof - Google Patents

Purine derivatives and medicaments thereof

Info

Publication number
NZ329431A
NZ329431A NZ329431A NZ32943197A NZ329431A NZ 329431 A NZ329431 A NZ 329431A NZ 329431 A NZ329431 A NZ 329431A NZ 32943197 A NZ32943197 A NZ 32943197A NZ 329431 A NZ329431 A NZ 329431A
Authority
NZ
New Zealand
Prior art keywords
prophylaxis
cell
medicaments
purine derivatives
inhibitors
Prior art date
Application number
NZ329431A
Inventor
Anuschirwan Peyman
Jochen Knolle
Volkmar Wehner
Gerhard Breipohl
Jean-Francois Gourvest
Denis Carniato
Thomas Richard Gadek
Original Assignee
Genentech Inc
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoechst Ag filed Critical Genentech Inc
Publication of NZ329431A publication Critical patent/NZ329431A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

isclosed are compounds of formula I and Ia which are useful as inhibitors of bone resorption by osteoclasts, inhibitors of tumor growth, as an anti-inflammatory, for the prophylaxis of cardiovascular disorders, for the prophylaxis of nephropathies or retinopathies, or as a vitronectin receptor antagonist for the prophylaxis of illnesses based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes.
NZ329431A 1996-12-20 1997-12-18 Purine derivatives and medicaments thereof NZ329431A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (en) 1996-12-20 1996-12-20 Substituted purine derivatives, processes for their preparation, agents containing them and their use

Publications (1)

Publication Number Publication Date
NZ329431A true NZ329431A (en) 2000-01-28

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ329431A NZ329431A (en) 1996-12-20 1997-12-18 Purine derivatives and medicaments thereof

Country Status (22)

Country Link
EP (1) EP0853084B1 (en)
JP (1) JP4620190B2 (en)
KR (1) KR19980064655A (en)
CN (2) CN1101816C (en)
AR (1) AR010700A1 (en)
AT (1) ATE404562T1 (en)
AU (1) AU728865B2 (en)
BR (1) BR9706387A (en)
CA (1) CA2225366C (en)
CZ (1) CZ294437B6 (en)
DE (2) DE19653646A1 (en)
HK (1) HK1012190A1 (en)
HU (1) HUP9702507A3 (en)
ID (1) ID19254A (en)
IL (1) IL122642A0 (en)
NO (1) NO314583B1 (en)
NZ (1) NZ329431A (en)
PL (1) PL323969A1 (en)
RU (1) RU2228335C2 (en)
TR (1) TR199701647A2 (en)
TW (1) TW523515B (en)
ZA (1) ZA9711317B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074543B1 (en) 1998-04-09 2012-01-25 Meiji Seika Pharma Co., Ltd. Aminopiperidine derivatives as integrin alpha v beta 3 antagonists
CA2356748A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (en) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Process for the preparation of inhibitors of cell adhesion
KR100438820B1 (en) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Method for manufacturing compound semiconductor substrate of III-V group
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
FR2847254B1 (en) * 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
DK2206727T3 (en) 2007-10-11 2015-07-06 Daiichi Sankyo Co Ltd ANTIBODY SPECIFIC TO OSTEOKLASTRELATERET PROTEIN Siglec-15
JP2011503206A (en) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド Therapeutic compounds and methods of use thereof in the treatment of diseases and disorders
AU2010235453B2 (en) 2009-04-09 2013-10-03 Daiichi Sankyo Company,Limited Anti-Siglec-15 antibody
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2625205A2 (en) 2010-10-05 2013-08-14 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
SG11201405966PA (en) 2012-03-30 2014-11-27 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
RU2016146826A (en) 2014-05-30 2018-07-04 Пфайзер Инк. CARBONITRIL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (en) * 1966-12-10 1972-09-13
JPS6396663A (en) * 1986-10-13 1988-04-27 Mita Ind Co Ltd Electrostatic charge image developing toner
JPS6396553A (en) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd Packing material
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
MX9207334A (en) * 1991-12-18 1993-08-01 Glaxo Inc NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
FR2700337B1 (en) * 1993-01-11 1995-04-14 Lafon Labor Imidazopyridine-2-one derivatives, their preparation process and their use in therapy.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (en) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhesion receptor antagonists
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
JPH10504808A (en) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
WO1996020212A2 (en) * 1994-12-28 1996-07-04 Buchardt, Dorte Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JP2001518054A (en) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ，インコーポレーテッド PNA-DNA chimera and PNA synthon for chimera synthesis
JPH1025294A (en) * 1996-03-26 1998-01-27 Akira Matsuda Condensed heterocyclic derivative, its production and malignant tumor therapeutic agent containing the same
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734783T2 (en) * 1996-07-24 2006-08-17 Buchardt, Dorte PEPTID NUCLEIC ACIDS WITH INCREASED BINDING SAFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
CA2225366C (en) 2006-10-10
CZ411497A3 (en) 1998-07-15
HUP9702507A2 (en) 1999-05-28
AU4846697A (en) 1998-06-25
NO314583B1 (en) 2003-04-14
JP4620190B2 (en) 2011-01-26
CA2225366A1 (en) 1998-06-20
BR9706387A (en) 2000-03-14
DE19653646A1 (en) 1998-06-25
NO975977L (en) 1998-06-22
AR010700A1 (en) 2000-06-28
AU728865B2 (en) 2001-01-18
NO975977D0 (en) 1997-12-19
ID19254A (en) 1998-06-28
TR199701647A3 (en) 1998-07-21
HU9702507D0 (en) 1998-03-02
EP0853084A2 (en) 1998-07-15
HUP9702507A3 (en) 1999-12-28
KR19980064655A (en) 1998-10-07
CN1101816C (en) 2003-02-19
TR199701647A2 (en) 1998-07-21
ZA9711317B (en) 1998-06-22
MX9710277A (en) 1998-10-31
EP0853084A3 (en) 1998-09-09
CZ294437B6 (en) 2005-01-12
JPH10182645A (en) 1998-07-07
HK1012190A1 (en) 1999-07-30
TW523515B (en) 2003-03-11
PL323969A1 (en) 1998-06-22
IL122642A0 (en) 1998-08-16
DE59712958D1 (en) 2008-09-25
ATE404562T1 (en) 2008-08-15
CN1495184A (en) 2004-05-12
CN1193623A (en) 1998-09-23
RU2228335C2 (en) 2004-05-10
EP0853084B1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
NZ329431A (en) Purine derivatives and medicaments thereof
MX9805253A (en) Vitronectin receptor antagonists.
CA2211270A1 (en) Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
MX9702070A (en) New osseous resorption inhibitors and vitronectine receptor antagonists.
ZA200002263B (en) Process for the synthesis of nucleoside analogs.
IL147184A0 (en) Substituted benzimidazole
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
ATE250623T1 (en) 4'-C-ETHYNYL PURINE NUCLEOSIDES
CA2308098A1 (en) Fastening member
MXPA03009750A (en) Chemical compounds.
NZ505613A (en) Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
AP2000001898A0 (en) Vitronectin receptor antagonists
NO975975L (en) Vitronectin receptor antagonists, preparation and use thereof
BG106930A (en) Substituted phenyl-piperazine derivatives, their preparation and use
TR200000786T2 (en) Vitronectin receptor antagonist
MX9604368A (en) Antagonists of endothelin receptors.
SI1644389T1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
MXPA05005198A (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands.
WO2003002580A8 (en) 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
HK1034512A1 (en) Process for the production of purine derivatives and intermediates therefor
HK1078781A1 (en) Processes for preparing 1,3-dioxolane nucleosides
NZ516058A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
AU2001293791A1 (en) Process for the preparation of vitronectin receptor antagonists
MY122631A (en) Substituted purine derivatives as inhibitors of cell adhesion

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)